Oruka Therapeutics (ORKA) Price Target Increased to $120 by Leerink

Leerink Partners raised the price target for Oruka Therapeutics, Inc. (ORKA) to $120 from $109 on April 30, maintaining an Outperform rating. On April 27, ORKA announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, revealing a 63.5% response rate at Week 16 for moderate-to-severe plaque psoriasis. The trial's favorable safety profile aligns with the IL-23p19 class of therapies. Long-term data from this study is expected in H2 2026, which may influence investor sentiment toward ORKA and its pipeline of monoclonal antibodies.